Add Yahoo as a preferred source to see more of our stories on Google. Lynk Pharmaceuticals' next generation JAK inhibitor Lynk Pharmaceuticals has posted positive topline results from a Phase III ...
Please provide your email address to receive an email when new articles are posted on . Understanding of the safety and efficacy of JAK inhibitors continues to evolve. Real-world data sheds light on ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So, the first JAK inhibitor came to market ...
Acne is a common and clinically relevant adverse event among patients with IBD receiving JAK inhibitors. Acne occurs in 8.6% of individuals with inflammatory bowel diseases (IBD) who are receiving ...
Janus kinase (JAK) inhibitors had a marginally superior effect on pain relief when compared with tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA), particularly when ...
JAK inhibitors increased the risk of herpes zoster (HZ) and upper respiratory tract (URT) infections in patients with atopic dermatitis (AD). On subsequent analysis, however, that increase diminished ...
A panelist discusses how the comprehensive ADVANCES safety monitoring system data presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) revealed distinct infection risk ...
Adverse events profile of novel agents targeting immune checkpoints beyond PD-1/PD-L1 and CTLA-4 in solid tumors: A meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Existing autoimmune drugs may prevent or reverse a serious side effect faced by patients with cancer. Immunotherapy-induced type 1 diabetes is a serious side effect faced by some patients receiving ...
At 54 weeks in the STOP-HS1 and STOP-HS2 trials, up to 71.4% of patients taking povorcitinib achieved at least a 50% reduction from baseline in the total abscess and inflammatory ...
How does the safety of oral JAK inhibitors compare with that of dupilumab in patients with atopic dermatitis (AD)? To find out, a group of dermatologists and immunologists with Harvard Medical School ...
Spleen size, blood counts and symptom burden are some of the factors cancer teams take into account when selecting which of the four JAK inhibitors to treat patient with myelofibrosis. Several patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results